维普中文期刊产品整合服务
27篇 您的检索式:作者名="Cheung HC"
    题名 作者 年代 出处 被引量
1Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy显示文摘Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies.Man Fai Law Rita Ho Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam 2016World Journal of Gastroenterology2016,22,28:10
2Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines 显示文摘Cheung HC Hal T Zhu W 2009Bra/n2009,132,8:1
3Cyclic fatigue and torsional resistance of two new nickel-titanium instruments used in reciprocation motion:Reciproc versus Wave One显示文摘Kim HC Kwak SW Cheung GS 2012J Endod2012,38,4:1
4Cyclic fatigue and tor- sional resistance of two new nickel-titanium instruments used in reciprocation motion : reciproc versus waveOne 显示文摘Kim HC Kwak SW Cheung SP 2012J Endod2012,38,4:1
5Local recurrence after subtotal esophagectomy for squammous cell carcinoma显示文摘Tam PC Siu KFS Cheung HC 1987Ann Surg1987,205,2:1
6Dynamic responses of infinite continuous beams subjected to a moving forcean exact method 显示文摘Cai CW Cheung YK Chart HC 1988Journal of Sound and Vibration1988,123,:1
7Influence of regional pollution out flow on the concentrations of fine particulate matter and visibility in the coastal area of southern China显示文摘CHEUNG HC WANG BAUMANNK e tal 2005Atmospheric Environment2005,39,34:1
8Comparison of RapidAre and static gantry intensity-modulated radiotherapy for nasopharyngeal carcinoma显示文摘Cheung WK Lee KH Cheng HC 2010J Hong Kong Col Radiol2010,13,:1
9Cyclic fatigue and torsional resistance of two new nickel-titanium instruments used in reciprocation motion:Reciproc versus WaveOne显示文摘Kim HC Kwak SW Cheung GS 0,,04:1
10Is pyloroplasty necessary in esophageal replacement by stomach? A prospective randomized controlled trial 显示文摘Cheung HC Siu KF Wong J 1987Sttrgery1987,102,1:1
11Heterogeneous hardening plasticity model for concrete显示文摘CHAN HC CHEUNG YK HUANG YP 0,,:1
12Local recurrences after subtotal esophagectomy for squamous cell carcinoma 显示文摘Tam PC Cheung HC Ma L 1987Ann Surg1987,205,:1
13Shrinkage of the esophagus after resection for carcinoma 显示文摘Siu KF Cheung HC Wang J 1986Ann Surg1986,203,2:1
14Comparison of forces generated during root canal shaping and residual stresses of three nickel-titanium rotary files by using a three-dimensional finite-element analysis显示文摘Kim HC Cheung GS Lee CJ 2008J Endod2008,34,6:1
15Improved lung function and symptom control with formoterol on demand in asthma 显示文摘Cheung D Van Klink HC Aalbers R 2006Eur Respir J2006,27,3:1
16Cyclic fatigue and torsional resistance of two new nickel-titanium instruments used in reciprocation motion:Reciproc versus WaveOne显示文摘Kim HC Kwak SW Cheung GS 2012J Endod2012,38,4:1
17Comparison of forces genera- ted during root canal shaping and residual stresses of three nickel- titanium rotary files by using a three-dimensional finite-element analysis 显示文摘Kim HC Cheung GS Lee C J 2008J Endod2008,34,6:1
18Comparison of forces gener- ated during root canal shaping and residual stresses of three nickel-titanium rotary files by using a three-dimensional fi- nite-element analysis 显示文摘Kim HC Cheung GS Lee C J 2008J Endod2008,34,6:1
19Coronary artery fistulas: long term results of surgical correction 显示文摘Cheung DC Au WK Cheung HC 2001Ann Thorac Surg2001,71,:1
20RapidArc和静态调强在鼻咽癌放疗中的比较研究显示文摘Cheung WK Lee KH Cheng HC 2010香港放射医学杂志2010,,:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费